Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 4/20 | 0.32 |
| ▸ | CA2 | P00918 | 4/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24217610 | 0.94 | FOLH1 (0.46) | FOLH1FFAR4POLBBCHEHSD17B10 | |
| SCHEMBL27329952 | 0.89 | FOLH1 (0.46) | FOLH1FFAR4POLBCA1CA2 | |
| SCHEMBL29299539 | 0.85 | FOLH1 (0.43) | FOLH1FFAR4POLBCA1CA2 | |
| SCHEMBL1404313 | 0.81 | FOLH1 (0.56) | FOLH1FFAR4BACE1CA1CA2 | |
| SCHEMBL22131080 | 0.80 | FOLH1 (0.52) | FOLH1BACE1HSD17B10 | |
| SCHEMBL27303602 | 0.78 | FOLH1 (0.52) | FOLH1FFAR4POLBBACE1CA1 | |
| SCHEMBL25741233 | 0.78 | FOLH1 (0.52) | FOLH1FFAR4POLBBACE1HSD17B10 | |
| SCHEMBL25573716 | 0.77 | FOLH1 (0.48) | FOLH1POLBBCHECA1CA2 | |
| SCHEMBL25801389 | 0.76 | FOLH1 (0.52) | FOLH1FFAR4POLBBACE1CA1 | |
| SCHEMBL19079011 | 0.76 | FOLH1 (0.49) | FOLH1FFAR4CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210009715-A1 | NOVEL PSMA-BINDING AGENTS AND USES THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2021-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210009715-A1 | NOVEL PSMA-BINDING AGENTS AND USES THEREOF | FOLH1, PSMA3, PSMA2 | FOLH1 1/4885FFAR4 2802/4885POLB 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.